Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "Phase-II"

570 News Found

Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents
News | January 14, 2026

Bayer acquires Attralus’ cutting-edge cardiac amyloidosis imaging agents

The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics


GSK’s Exdensur wins Japanese nod for severe asthma
Drug Approval | January 08, 2026

GSK’s Exdensur wins Japanese nod for severe asthma

The approval follows robust data from the SWIFT and ANCHOR Phase III trials


Rapid-acting ADHD treatment Azstarys now approved in China
Drug Approval | January 08, 2026

Rapid-acting ADHD treatment Azstarys now approved in China

ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood


Wockhardt files marketing authorisation application for WCK 5222 with EMA
News | January 08, 2026

Wockhardt files marketing authorisation application for WCK 5222 with EMA

WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation


GSK’s Nucala approved in China for COPD with high eosinophils
Drug Approval | January 07, 2026

GSK’s Nucala approved in China for COPD with high eosinophils

Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL


HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer
News | January 01, 2026

HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer

ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium


Chugai’s Tecentriq gets green light in Japan for hard-to-treat Thymic Carcinoma
Drug Approval | December 27, 2025

Chugai’s Tecentriq gets green light in Japan for hard-to-treat Thymic Carcinoma

The drug had previously received orphan drug designation for this rare cancer on March 31, 2025


Symbiosis rolls out first 10,000 vial batch at Stirling Facility
News | December 27, 2025

Symbiosis rolls out first 10,000 vial batch at Stirling Facility

This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines


Biofabri and Bharat Biotech ink tech transfer pact to boost global TB vaccine access
News | December 26, 2025

Biofabri and Bharat Biotech ink tech transfer pact to boost global TB vaccine access

BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia